Tumor suppressor genes as cancer therapeutics

Drug News and Perspectives

Volumn 20, Issue 8, 2007, Pages 511-520

  Vattemi, Emanuela ^a   Claudio, Pier Paolo ^b  

^a Central Regional Hospital   (Italy)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME; METHOTREXATE; NAVELBINE; PACLITAXEL; PARVOVIRUS VECTOR; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETROVIRUS VECTOR; VIRUS VECTOR;

BYSTANDER EFFECT; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG SPECIFICITY; EDEMA; FEVER; GENE EXPRESSION REGULATION; GENE TARGETING; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HERPES SIMPLEX VIRUS; HUMAN; HYPOTENSION; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PAIN; PROMOTER REGION; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CELL CYCLE; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; MODELS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 38749151593     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.8.1157613     Document Type: Review

References (86)

1. Weinberg, R.A. Tumor suppressor genes. Science 1999, 254(5035): 1138-45.
2. Hakem, R. and Mak, T.W. Animal models of tumor-suppressor genes. Ann Rev Genet 2001, 35: 209-41.
3. Macleod, K. Tumor suppressor genes. Curr Opin Genet Dev 2000, 10(1): 81-93.
4. Kinzler, K.W. and Vogelstein, B. Cancer-suceptibility genes. Gatekeepers and caretakers. Nature 763, 386(6627): 761.
5. Lee, W.H., Bookstein, R., Honf, F. et al. Human retinoblastoma susceptibility gene: Cloning, identification and sequence. Science 1987, 235(4794): 1394-9.
6. Mayol, X., Grana, X., Baldi, A. et al. Cloning a new member of the retinoblastoma gene family (pRB2) which binds to the E1A transforming domain. Oncogene 1993, 8(9): 2561-6.
7. Stiegler, P., Kasten, M. and Giordano, A. The RB family of cell cycle regulatory factors. J Cell Biochem Suppl. 1998, 31: 30-6.
8. Harbour, J.W. and Dean, D.C. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev 2000, 14(19): 2393-409.
9. Nevins, J.R. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998, 9(8): 585-93.
10. Dannenberg, J.H., Schuijff, L., Dekker, M., van der Valk, M. and Riele, H.T. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev 2004, 18(23): 2952-62.
11. Claudio, P.P., Howard, C.M., Baldi, A. et al. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 1994, 54(21): 5556-60.
12. Moberg, K., Starz, M.A., Lees, J.A. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol 1996, 16(4): 1436-49.
13. Sellers, W.R., Kaelin, W.G. Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997, 15(11): 3301-12.
14. Masciullo, V., Khalili, K. and Giordano, A. The Rb family of cell cycle regulatory factors: Clinical implications. Int J Oncol 2000, 17(5): 897-902.
15. Vogelstein, B., Lane, D. and Levine, A.J. Surfing the p53 network. Nature 2000, 408(6810): 307-10.
16. Kastan, M.B., Cancan, C.E. and Leonard, C.J. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995, 14(1): 3-15.
17. Prives, C. and Hall, P.A. The p53 pathway. J Pathol 1999, 187(1): 112-26.
18. El Deiry, W.S. Regulation of p53 downstream genes. Semin Cancer Biol 1998, 8(5): 345-57.
19. El Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75(4): 817-25.
20. Caelles, C., Helmberg, A. and Karin, M. p53-dependent apoptosis in the absence of transcriptional activation of p53 target genes. Nature 1994, 370(6486): 220-3.
21. Burns, T. and El Deiry, W. The p53 pathway and apoptosis. J Cell Physiol 1999, 181(15): 231-9.
22. Alarcon-Vargas, D. and Ronai, Z. p53-Mdm2-the affair that never ends. Carcinogenesis 2002, 23(4): 541-7.
23. Kamijo, T., Zindy, F., Roussel, M.F. et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91(15): 649-59.
24. Hollstein, M., Rice, K., Greenblatt, M.S., Soussi, T., Fuchs, R., Sorlie, T. et al. Database of p53 gene somatic mutations in human tumours and cell lines. Nucleic Acids Res 1994, 22(17): 3551-5.
25. Soussi, T. p53 mutations and resistance to chemotherapy. Cancer Cell 2003, 3(4): 303-5.
26. Weller, M. Predicting response to cancer chemotherapy: The role of p53. Cell Tissue Res 1998, 292(3): 435-45.
27. Gottesman, M.M. Cancer gene therapy: An awkward adolescence. Cancer Gene Ther 2003, 10(7): 501-8.
28. Buchschacher,G.L. Jr. Introduction to retroviruses and retroviral vectors. Somat Cell Mol Genet 2000, 26(1-6): 1-11.
29. Miller, A.D. Retroviral vectors. Curr Top Microbiol Immunol 1992, 158: 1-24.
30. Russell, W.C. Update on adenovirus and its vectors. J Gen Virol 2000, 81(Pt. 11): 2573-604.
31. Seth, P. Adenoviral vectors. Adv Exp Med Biol 2000, 465: 13-22.
32. Tratschin, J.D., Miller, I.L., Smith, M.G. and Carter, B.J. Organization of adenoassociated virus vector for high frequency integration, expression and rescue of genes in mammalian cells. Mol Cell Biol 1985, 5(11): 3251-60.
33. Fink, D.J. and Glorioso, J.C. Engineering herpes simplex virus vectors for gene transfer to neurons. Nat Med 1997, 3(3): 357-9.
34. Horn, N.A., Meek, J.A., Budahazi, G. and Marquet, M. Cancer gene therapy using plasmid DNA: Purification of DNA for human clinical trials. Hum Gene Ther 1995, 6(5): 565-73.
35. Liu, F., Song, Y. and Liu, D. Hydrodinamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999, 6(7): 1258-66.
36. Ramesh, R., Saeki, T., Templeton, N.S. et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 2001, 3(3): 337-50.
37. Song, Y.K., Liu, F., Chu, S. and Liu, D. Characterization of cationic liposome mediated gene transfer in vivo by intravenous administration. Hum Gene Ther 1997, 8(13): 1585-94.
38. Ito, I., Began, G., Mohiuddin, I. et al. Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol Ther 2003, 7(3): 409.
39. Felnerova, D., Viret, J.F., Gluck, R. and Moser, C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004, 15(6): 518-29.
40. Kirchweger, G. Nanoparticles-the next big thing? Mol Ther 2002, 6(3): 301-2.
41. Vijayanathan, V., Thomas, T. and Thomas, T.J. DNA nanoparticles and development of DNA delivery vehicles for gene therapy. Biochemistry 2002, 41(48): 14085-94.
42. Sohn, R.L., Murray, M.T., Schwarz, K. et al. In vivo particle mediated delivery to mammalian tissues: Ballistic and biologic effects. Wound Repair Regen 2001, 9(4): 287-96.
43. Udvardi, A., Kufferath, I., Grutsch, H., Zatloukal, K. and Volc-Platzer, B. Uptake of exogenous DNA via the skin. J Mol Med 1999, 77(10): 744-50.
44. Yang, N.S., Burkholder, J., Roberts, B., Martinell, B. and McCabe, D. In vivo and in vitro gene transfer to mammallian somatic cells by particle bombardament. Proc Natl Acad Sci U S A 1990, 87(24): 9568-72.
45. Kanerva, A. and Hemminki, A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004, 110(4): 475-80.
46. Blackwell, J.L., Miller, R., Douglas, J.T. et al. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1999, 125(8): 856-63.
47. Kasono, K., Blackwell, J.L., Douglas, J.T. et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 1999, 5(9): 2571-9.
48. Vile, R.G., Hart, I.R. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993, 53(5): 962-7.
49. Morelli, A.E., Larregina, A.T., Smith-Arica, J. et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule FAS ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol 1999, 80(Pt. 3): 571-83.
50. Gao, Z., Fields, J.Z. and Boman, B.M. Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug resistant colon-adenocarcinoma cells. Int J Cancer 1999, 82(3): 346-52.
51. Rodriguez, R., Schuur, E.R., Lim, H.Y. et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1999, 57(13): 2559-63.
52. YU, D.C., Sakamoto, G.T. and Henderson, D.R. Identification of the transcriptional regulatory sequences of human kallicrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999, 59(7): 1498-504.
53. Hallenbeck, P.L., Chang, Y.N., Hay, C. et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999, 10(10): 1721-33.
54. Kurihara, T., Brough, D.E., Kovesdi, I. et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000, 106(6): 763-71.
55. Hernandez-Alcoceba, R., Pihalja, M., Wicha, M.S. et al. A novel, conditionally replicative adenovirus of the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther 2000, 11(6): 2009-24.
56. Hallahan, D.E., Mauceri, H.J., Seung, L.P. et al. Spatial and temporal control of gene therapy using ionising radiation. Nat Med 1995, 1(8): 786-91.
57. Marples, B., Scott, S.D., Hendry, J.H., Embleton, M.J., Lashford, L.S. and Margison, G.P. Development of syntetic promoters for radiation-mediated gene therapy. Gene Ther 2000, 7(6): 511-7.
58. Weichselbaum, R.R., Hallahah, D., Fuks, Z. and Kufe, D. Radiation induction of imme diate early genes: Effectors of the radiation-stress response. Int J Radiat Oncol Biol Phys 1994, 30(1): 229-34.
59. Nettelbeck, D.M., Jerome, V. and Muller, R. Gene therapy: Designer promoters for tumor targeting. Trends Genet 2000, 16(4): 174-81.
60. Nielsen, L.L., Dell, J., Maxwell, E. et al. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 1997, 4(15): 129-38.
61. Fujiwara, T., Grimm, E.A., Mukhopadhyay, T. et al A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993, 53(15): 4129-33.
62. Fujiwara, T., Cai, D.W., Georges, R.N. et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994, 86(15): 1437-8.
63. Wang, J.X., Bucana, C.D., Roth, J.A., Zhang, W.W. et al. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gen Ther 1995, 2(15): 9-17.
64. Hamada, K., Alemany, R., Zhang, W.W. et al. Adenovirus-mediated transfer of a wildtype p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996, 56(13): 3047-54.
65. Wolf, J.K., Mills, G.B., Bazzet, L., Bast, R.C. Jr., Roth, J.A., Gershenson, D.M. Adenovirus-mediated p53 growth inhibition of cancer cells is independent of endogenous p53 status. Gynecol Oncol 1999, 75(2): 261-6.
66. Peng, K.W. and Vile, R. Vector development for cancer gene therapy. Tumor Targeting 1999, 4: 3-11.
67. Mesnil, M. and Yamasaki, H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res 2000, 60(15): 3989-99.
68. Shao, R., Xia, W. and Hung, M.C. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. Cancer Res 2000, 60(12): 3123-6.
69. Nishizaki, M., Fujiwara, T., Tanida, T. et al. Recombinant adenovirus expressing wildtype p53 is antiangiogenic: A proposed mechanism for bystander effect. Clin Cancer Res 1999, 5(5): 1015-23.
70. Ramesh, R., Marrogi, A.J., Munshi, A., Abboud, C.N. and Freeman, S.M. In vivo analysis of the "bystander effect": A cytokine cascade. Exp Hematol 1996, 24(7): 829-38.
71. Kianmanesh, A.R., Perrin, H., Panis, Y. Fabre, M. Nagy, H.J., Houssin, D. and Klatzmann, D.A. "Distant" bystander effect of suicide gene therapy: Regression of non-transduced tumors together with a distant transduced tumor. Human Gene Ther 1997, 8(15): 1807-14.
72. Nielsen, L.L. NK cells mediate the antitumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model. Oncol Rep 2000, 7(1): 151-5.
73. Roth, J.A., Nguyen, D., Lawrence, D.D. et al. Retrovirus mediated wild type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996, 2(15): 985-91.
74. Swisher, S.G., Roth, J.A., Nemunaitis, J. et al.Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst (Bethesda) 1999, 91(9): 763-71.
75. Clayman, G.L., El-Naggar, A.K., Lipmann, S.L. et al. Adenovirus- mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998, 16(6): 2221-32.
76. Clayman, G.L., Frank, D.K., Bruso, P.A. and Goepfert, H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in head and neck cancers. Clin Cancer Res 1999, 5(7): 1715-22.
77. Nemunaitis, J., Bier-Laning, C.M., Costenta-Figueiras, M., Yver, A. and Dreiling, L.K. Three phase II trials of intratumoral injection with a replication deficient adenovirus carrying the p53 gene (AD5CMV-p53) in patients with recurrent refractory head and neck cancer. Proc Am Soc Clin Oncol (ASCO) 1999, 19: Abst 1661.
78. Lang, F.F., Bruner, J.M., Fuller, G.N. et al. Phase I trial of adenovirus-mrdiated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol 2003, 21(13): 2508-18.
79. Nemunaitis, J., Swisher, S.G., Timmons, T. et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J Clin Oncol 2000, 18(3): 609-22.
80. Schuler, M., Herrmann, R., De Greve, J. et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter Phase II study. J Clin Oncol 2001, 19(6): 1750-8.
81. Buller, R.E., Shahin, M.S., Horowitz J.A. et al. Long term follow up of patients with recurrent ovarian cancer after Adp53 gene replacement with SCH85500. Cancer Gene Ther 2002, 9(7): 567-72.
82. Cristofanilli, M., Krishnamurthy, S., Guerra, L. et al. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: Safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 2006, 107(5): 935-44.
83. Swisher, S.G., Roth, J.A., Komaki, R. et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2002, 9(1): 93-101.
84. Peng, Z., Han, D., Zhang, S. et al. Clinical evaluation of safety and efficacy of intratumoral administration of a recombinant adenoviral-p53 anticancer agent. Mol Ther 2003, 7(15): 422-3.
85. Alemany, R., Balague, C. and Curiel, D.T. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000, 18(7): 723-7.
86. Galanis, E. and Russell, S. Cancer Gene therapy clinical trials: Lessons for the future. Br J Cancer 2001, 85(10): 1432-6.